RNS Number : 6261N
OptiBiotix Health PLC
02 February 2021

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Proposed Director appointment
Directorate change

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it intends to appoint Stephen Hammond MP, as a Non- Executive Director of the Company, subject to the completion of regulatory due diligence being carried out by the Company's Nomad.

Stephen has been a Member of Parliament since 2005, fulfilling roles as Parliamentary Under Secretary of State for Transport from 2012 to 2014 and more recently Minister of State for the Department of Health and Social Care from 2018 to 2019.

Prior to his role in politics, Stephen had a successful career in finance at a leading fund management house and at a number of major European investment banks. He was a Director of the Equities division of Dresdner Kleinwort Benson from 1994 to 1998, a private bank providing financial services to high net worth individuals and corporate clients in the UK. After this he joined Commerzbank Securities, a leading international commercial bank described as 'Germany's Leading Brokerage Firm' of the past 10 years (https://tinyurl.com/y5re88mg), with branches and offices in nearly 50 countries. He was with Commerzbank Securities from 1998 until 2003. During this time, Stephen was promoted to Director in Pan European Research, with the responsibility for 70 professionals based in London and across Europe, before becoming an MP in 2005.

A further announcement will be made in due course.

Neil Davidson, Chairman of OptiBiotix commented: "*Stephen's appointment reflects the continued evolution and ambition of the Board as the Company moves into the next phase of its development in becoming a profitable international business with global brands. Stephen's international understanding of healthcare, finance and experience of working in senior positions within finance and government complements the current Board's wealth of experience.*

"The Company anticipate that there will be further additions and changes to the Board and management teams as it continues to grow sales, expand into international markets and commercialises its next generation products."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the content of this announcement.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman *Contact via Walbrook below*
Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti

Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)

Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the

amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADZGGZNMKGMZM